Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$13.11+1.47%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put REPL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Manage operating losses and cash burn: metric not reported.
View ThesisThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 84% in its worst 12-month stretch.
View RiskREPL's growth depends on gaining FDA approval for RP1 BLA. The company must manage operating losses and cash burn effectively. Revenue performance has been steady, but recent results missed expectations. REPL trades at a low confidence valuation, with no clean multiple to anchor. Peer multiples imply a price about 22% above where it trades. A sharp drop in price may indicate a repricing of the thesis. The primary risk is managing operating losses, which are not reported. This read is provisional.
Trailing returns as of 2026-09-14. REPL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering REPL (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for REPL in the last 4 months.
Continue this research
Compare REPL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| REPL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put REPL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Resubmit and gain FDA approval for RP1 BLA
FDA approval directly supports regulatory objective for RP1 BLA.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $13.11
The last 12 months of price, then the range of analyst 12-month targets from today’s $13.11.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Resubmit BLA for RP1 with FDA
Upgrade indicates positive sentiment on FDA resubmission.